LOEWE funding strengthens university alliance

Three new LOEWE projects, in which research teams from Goethe University Frankfurt and TU Darmstadt are involved, can commence their work on 1 January 2020. The project consortia will be supported for a period of four years with a total of more than 13 million euros within the framework of the 12th funding phase of the Hessian LOEWE research programme. This was announced by the Hessian Ministry for Science.

Professor Felix Hausch is standing in a lab behind test glass. He applies something with a pipette

Professor Dr. Felix Hausch, scientific coordinator of the LOEWE project TRABITA, picture: Katrin Binner

The new LOEWE project "Architecture of Order: Practices and discourses between design and knowledge" is located at Goethe University. Interdisciplinary groups will investigate the significance of architecture for social, cultural and scientific concepts of order and how concepts such as "security architecture" or "edifice of ideas" affect architectural discourse. The research partners are Technische Universität Darmstadt and the Max Planck Institute for European Legal History. The work of this focal point is intended to contribute to honing the architectural profile of the Rhine-Main region internationally.

How can we develop more effective active substances for proteins that have so far been inaccessible from a pharmacological point of view? This will be researched at TU Darmstadt by the new LOEWE project "TRABITA - Transient binding pockets for drug development”. Drugs usually unfold their potential by binding to disease-relevant proteins. Here it is important to understand the structure of a specific binding site in these proteins, the so-called binding pocket, and to develop improved drugs on this basis. Partners in the network are Goethe University Frankfurt and Hochschule Darmstadt.

Researchers from Goethe University Frankfurt and TU Darmstadt are also involved in the new LOEWE project "GLUE - GPCR Ligands for Underexplored Epitopes". This project, which is coordinated under the leadership of the University of Marburg, deals with the question of how drugs can be tailor-made for their targets so that they are targeted and better tolerated. Another partner is the Max Planck Institute for Heart and Lung Research in Bad Nauheim.